Abstract:OBJECTIVE:To evaluate the effectiveness of statin treatment strategies based on risk assessment for the primary prevention of cardiovascular diseases by the Western guidelines in a community-based Chinese population from economically developed areas using data from the Chinese electronic health records research in Yinzhou (CHERRY) study.METHODS:A Markov model was used to evaluate the effectiveness of the following statin treatment strategies, including: (1) usual care without cardiovascular risk assessment(Strategy 0); (2) using the World Health Organization (WHO) non-laboratory-based risk charts with statin treatment for high-risk group (risk ≥ 20%) (Strategy 1); (3) using the WHO laboratory-based risk charts with statin treatment for high-risk group (risk ≥ 20%) (Strategy 2); and (4) using the Prediction for Atherosclerotic cardiovascular disease Risk in China (China-PAR) model with statin treatment for high-risk group (risk ≥ 10%, Strategy 3). According to the guidelines, adults in the medium-risk group received lifestyle intervention, and adults in the high-risk group received life-style intervention and statin treatment under these strategies. The Markov model simulated different strategies for ten years (cycles) using parameters from the CHERRY study, published data, meta-analyses and systematic reviews for Chinese. The number of cardiovascular events or deaths, as well as the number need to treat (NNT) with statin per cardiovascular event or death prevented, were calculated to compare the effectiveness of different strategies. One-way sensitivity analysis on the uncertainty of incidence rate of cardiovascular diseases, and probabilistic sensitivity analysis on the uncertainty of hazard ratios of interventions were conducted.RESULTS:Totally 225 811 Chinese adults aged 40-79 years without cardiovascular diseases at baseline were enrolled. In contrast to the usual care without risk assessment-based statin treatment strategy, Strategy 1 using the WHO non-laboratory-based risk charts could prevent 3 482 [95% uncertainty interval (UI): 2 110-4 661] cardiovascular events, Strategy 2 using the WHO laboratory-based risk charts could prevent 3 685 (95%UI: 2 255-4 912) events, and Strategy 3 using the China-PAR model could prevent 3 895 (95%UI: 2 396-5 181) events. NNTs with statin per cardiovascular event prevented were 22 (95%UI: 14-54), 21 (95%UI: 14-52), and 27 (95%UI: 17-67), respectively. Strategy 3 could prevent more cardiovascular events, while Strategies 1 and 2 required fewer numbers need to treat with statin per cardiovascular event prevented. The results were consistent in the sensitivity analyses.CONCLUSION:The statin treatment strategies based on risk assessment for the primary prevention of cardiovascular diseases recommended by the Western guidelines could achieve substantive health benefits in adults from developed areas of China. Using the China-PAR model for cardiovascular risk assessment could prevent more cardiovascular diseases while using the WHO risk charts seems more efficient.

Sticking to Use Statin Dose Treatment as Main Rhyme

Utilization Study of Lipid-lowering Drugs in Hangzhou District

Achievement of Low-Density Lipoprotein Cholesterol Targets in Chinese Patients with Atherosclerotic Cardiovascular Disease after Receiving Statins and Ezetimibe

Efficacy of Statin Monotherapy or in Combination with Coenzyme A Capsule in Patients with Metabolic Syndrome and Mixed Dyslipidemia

Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy

Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.

Factors Influencing Low-Density Lipoprotein Cholesterol Target Achievement in Primary Care - Results from DYSIS China.

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China

[Chinese guideline for lipid management (primary care version 2024)].

2023 Chinese guideline for lipid management

Contemporary Management And Attainment Of Cholesterol Targets For Patients With Dyslipidemia In China

The second multi-center survey of dyslipidemia management in China: goal attainment rate and related factors]

Research progress on safety of high-intensity statin therapy in Chinese patients with acute coronary syndrome

A stepped and synthetic strategy for clinical lipid-lowering therapy

Two questions of reducing LDL-C by statins

Interpretation of Chinese Expert Consensus on the Diagnosis and Management Strategy of Patients with Statin Intolerance: A guiding file for helping to lipid management for Chinese population

STATINS ADHERENCE AND ITS RISK FACTORS ANALYSIS IN CHINESE ASCVD PATIENTS BASED ON A PROVINCIAL CLAIM DATA

[Effectiveness of Statin Treatment Strategies for Primary Prevention of Cardiovascular Diseases in a Community-Based Chinese Population: A Decision-Analytic Markov Model].

Managing Hypercholesterolemia and Preventing Cardiovascular Events in Elderly and Younger Chinese Adults: Focus on Rosuvastatin

[Status of Cholesterol Goal Attainment for the Primary and Secondary Prevention of Atherosclerotic Cardiovascular Disease in Dyslipidemia Patients Receiving Lipid-Lowering Therapy: DYSIS-China Subgroup Analysis].

Statins therapy in the elderly:a review on treatment of dyslipidemia